<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ogdie, Alexis</style></author><author><style face="normal" font="default" size="100%">Song, Chao</style></author><author><style face="normal" font="default" size="100%">Middaugh, Nicole</style></author><author><style face="normal" font="default" size="100%">Marchese, Maya</style></author><author><style face="normal" font="default" size="100%">Eliot, Melissa</style></author><author><style face="normal" font="default" size="100%">Low, Robert</style></author><author><style face="normal" font="default" size="100%">Mease, Philip J.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Who Achieves Minimal and Very Low Disease Activity in Psoriatic Arthritis? An Analysis of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of Rheumatology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2026-08-01 04:00:22</style></date></pub-dates></dates><elocation-id><style  face="normal" font="default" size="100%">jrheum.2025-1171</style></elocation-id><doi><style  face="normal" font="default" size="100%">10.3899/jrheum.2025-1171</style></doi><volume><style face="normal" font="default" size="100%"></style></volume><issue><style face="normal" font="default" size="100%"></style></issue><abstract><style  face="normal" font="default" size="100%">Objective To evaluate the achievement of minimal disease activity (MDA) and very low disease activity (VLDA) in patients with psoriatic arthritis (PsA) treated in a real-world clinical setting with biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).Methods This study included patients with a diagnosis of PsA treated with an approved b/tsDMARD who were enrolled in the CorEvitas PsA/Spondyloarthritis (SpA) Registry (March 2013 – September 2023). MDA/VLDA achievement was assessed at the follow-up registry visit, 6 (range: 5–9) months post-index (b/tsDMARD initiation).Results At the follow-up registry visit, 17.68% (370/2,093) and 7.51% (187/2,491) of patients achieved MDA and VLDA, respectively. Baseline characteristics including female sex, higher baseline fatigue and pain scores, and previous treatment with b/tsDMARDs were associated with a lower likelihood of achieving MDA/VLDA. Higher European Quality of Life 5-Dimension 3- Level (EQ-5D-3L) scores and b/tsDMARD monotherapy treatment were associated with a higher likelihood of achieving MDA. Among MDA/VLDA non-achievers, 23.10% (398/1,723) and 10.24% (236/2,304) missed MDA/VLDA achievement by 1 criterion, respectively. At the follow-up registry visit, pain was the most commonly unmet criterion across the overall MDA non-achiever (95.41%) and VLDA nonachiever (87.02%) cohorts. Other commonly unmet criteria were the Patient Global Assessment of arthritis and psoriasis (MDA non-achievers: 89.32%; VLDA non-achievers: 75.87%) and Health Assessment Questionnaire-Disability Index (MDA non-achievers: 80.91%; VLDA nonachievers: 67.01%).Conclusion Despite receiving b/tsDMARD treatment for PsA, most patients did not achieve MDA or VLDA, with the most commonly unmet criteria being pain and other patient-reported outcomes. These findings indicate opportunities to improve PsA management.</style></abstract></record></records></xml>